COMMUNIQUÉS West-GlobeNewswire

-
Irvine Facial Plastic Surgeon Distinguishes Between Lip Enhancement Options
28/11/2017 -
PDC Healthcare Launches New DuraProtect™ Laser Wristbands Engineered to Deliver Greater Durability at a Lower Cost
28/11/2017 -
Biothera Pharmaceuticals Enters Cancer Immunotherapy Clinical Trial Collaboration Agreement
28/11/2017 -
Chembio Diagnostics Awarded UNICEF Contract to Supply Point-of-Care DPP® Zika Assays and DPP® Micro Readers
28/11/2017 -
ToolGen, Inc. Announces Poster Presentation on CRISPR Technology at 2017 American Society of Hematology Annual Meeting
28/11/2017 -
CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic
28/11/2017 -
Cidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin (CD101 IV) in Invasive Fungal Infections
28/11/2017 -
Catalyst Biosciences Strengthens Clinical Hemophilia Programs with Additions to its Senior Leadership Team
28/11/2017 -
Skyline Medical and Helomics Announce a Joint Strategic Partnership with GLG Pharma
28/11/2017 -
Peregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement Agreement
28/11/2017 -
Healthwise® Orthopedic Decision Aids Receive Certification From Washington State Health Care Authority
28/11/2017 -
Insmed to Present at the Nasdaq 37th Annual Investor Conference
28/11/2017 -
CinRx Closes $10 Million Series B Financing
28/11/2017 -
Argos Provides Financial Update
28/11/2017 -
TESARO Announces Availability of VARUBI® (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States
28/11/2017 -
PhaseBio Enters Worldwide License Agreement with MedImmune for a Reversal Agent for Ticagrelor
28/11/2017 -
Provant Vice President of Client Management Elizabeth Merritt, Esq., is featured prominently in a recent Bloomberg Law article on wellness program incentives
28/11/2017 -
Neos Therapeutics to Participate in Two December Conferences
28/11/2017 -
Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting on February 17, 2018
28/11/2017
Pages